New insights into the role of antinuclear antibodies in systemic lupus erythematosus | Nature Reviews Rheumatology
Utility of serum ferritin and soluble interleukin-2 receptor as markers of disease activity in childhood systemic lupus erythematosus. - Abstract - Europe PMC
Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies | MJR - Mediterranean Journal of Rheumatology
Biomolecules | Free Full-Text | Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus
SLE Plasma Profiling Identifies Unique Signatures of Lupus Nephritis and Discoid Lupus | Scientific Reports
Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios in Systemic Lupus Erythematosus: Relation With Disease Activity and L
Towards a practical management of fatigue in systemic lupus erythematosus | Lupus Science & Medicine
Hyponatremia as an Inflammatory Marker of Lupus Activity Is a Fact or | OARRR
AVISE SLE Monitor is a Test For the Disease Activity of Lupus
Serum Metabolomic Signatures Can Predict Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus | Arteriosclerosis, Thrombosis, and Vascular Biology
Clinical disease activity and flare in SLE: Current concepts and novel biomarkers - ScienceDirect
Urinary biomarkers in lupus nephritis - ScienceDirect
Biomarkers of Disease Activity | Musculoskeletal Key
PDF] Predictors of outcome and immunological markers in patients with Systemic lupus erythematosus | Semantic Scholar
IJMS | Free Full-Text | Biomarkers Associated with Organ-Specific Involvement in Juvenile Systemic Lupus Erythematosus
Table 1 from Anti-nucleosome antibodies in patients with systemic lupus erythematosus: potential utility as a diagnostic tool and disease activity marker and its comparison with anti-dsDNA antibody. | Semantic Scholar
Systemic Lupus Erythematosus | NEJM
The Study of CD 69 as an Early Marker of SLE Activity in Pediatrics - SciAlert Responsive Version
Systemic Lupus Erythematosus (SLE) - Cancer Therapy Advisor
Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies: Trends in Molecular Medicine
Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus - ACR Meeting Abstracts
Lupus flareups cut in half by just 2,000 IU of vitamin D – RCT Dec 2012 | VitaminDWiki
Cureus | Systemic Lupus Erythematosus and Cardiovascular Disease
IJMS | Free Full-Text | Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-Analysis